<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">35075948</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>03</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>03</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1521-0464</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>29</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Drug delivery</Title>
          <ISOAbbreviation>Drug Deliv</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Improved transfer efficiency of supercharged 36 + GFP protein mediate nucleic acid delivery.</ArticleTitle>
        <Pagination>
          <StartPage>386</StartPage>
          <EndPage>398</EndPage>
          <MedlinePgn>386-398</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/10717544.2022.2030430</ELocationID>
        <Abstract>
          <AbstractText>The potential of nucleic acid therapeutics to treat diseases by targeting specific cells has resulted in its increasing number of uses in clinical settings. However, the major challenge is to deliver bio-macromolecules into target cells and/or subcellular locations of interest ahead in the development of delivery systems. Although, supercharged residues replaced protein 36 + GFP can facilitate itself and cargoes delivery, its efficiency is still limited. Therefore, we combined our recent progress to further improve 36 + GFP based delivery efficiency. We found that the penetration efficacy of 36 + GFP protein was significantly improved by fusion with CPP-Dot1l or treatment with penetration enhancer dimethyl sulfoxide (DMSO) <i>in vitro</i>. After safely packaged with plasmid DNA, we found that the efficacy of <i>in vitro</i> and <i>in vivo</i> transfection mediated by 36 + GFP-Dot1l fusion protein is also significantly improved than 36 + GFP itself. Our findings illustrated that fusion with CPP-Dot1l or incubation with DMSO is an alternative way to synergically promote 36 + GFP mediated plasmid DNA delivery <i>in vitro</i> and <i>in vivo</i>.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Lidan</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Microbiology and Immunology, Medical School, China Three Gorges University, Yichang, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University, Yichang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Geng</LastName>
            <ForeName>Jingping</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Microbiology and Immunology, Medical School, China Three Gorges University, Yichang, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University, Yichang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Linlin</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Microbiology and Immunology, Medical School, China Three Gorges University, Yichang, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University, Yichang, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Affiliated Ren He Hospital of China Three Gorges University, Yichang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Guo</LastName>
            <ForeName>Xiangli</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Microbiology and Immunology, Medical School, China Three Gorges University, Yichang, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University, Yichang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Tao</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>The First Clinical Medical College of China Three Gorges University, Yichang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fang</LastName>
            <ForeName>Yanfen</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>College of Biological and Pharmaceutical Sciences, China Three Gorges University, Hubei, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Belingon</LastName>
            <ForeName>Bonn</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>School of Medicine, Institute of Cell Engineering, Johns Hopkins University, Baltimore, MD, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wu</LastName>
            <ForeName>Jiao</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Affiliated Ren He Hospital of China Three Gorges University, Yichang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Manman</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University, Yichang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhan</LastName>
            <ForeName>Ying</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University, Yichang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shang</LastName>
            <ForeName>Wendou</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Microbiology and Immunology, Medical School, China Three Gorges University, Yichang, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University, Yichang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wan</LastName>
            <ForeName>Yingying</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Microbiology and Immunology, Medical School, China Three Gorges University, Yichang, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University, Yichang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Feng</LastName>
            <ForeName>Xuemei</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Microbiology and Immunology, Medical School, China Three Gorges University, Yichang, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University, Yichang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Xianghui</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Microbiology and Immunology, Medical School, China Three Gorges University, Yichang, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University, Yichang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Hu</ForeName>
            <Initials>H</Initials>
            <Identifier Source="ORCID">0000-0001-6132-8788</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Microbiology and Immunology, Medical School, China Three Gorges University, Yichang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Drug Deliv</MedlineTA>
        <NlmUniqueID>9417471</NlmUniqueID>
        <ISSNLinking>1071-7544</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D057846">Cell-Penetrating Peptides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D009696">Nucleic Acids</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>147336-22-9</RegistryNumber>
          <NameOfSubstance UI="D049452">Green Fluorescent Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.1.1.43</RegistryNumber>
          <NameOfSubstance UI="D011495">Histone-Lysine N-Methyltransferase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>YOW8V9698H</RegistryNumber>
          <NameOfSubstance UI="D004121">Dimethyl Sulfoxide</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D057846" MajorTopicYN="N">Cell-Penetrating Peptides</DescriptorName>
          <QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004121" MajorTopicYN="N">Dimethyl Sulfoxide</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016503" MajorTopicYN="N">Drug Delivery Systems</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049452" MajorTopicYN="N">Green Fluorescent Proteins</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006461" MajorTopicYN="N">Hemolysis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011495" MajorTopicYN="N">Histone-Lysine N-Methyltransferase</DescriptorName>
          <QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009696" MajorTopicYN="N">Nucleic Acids</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010316" MajorTopicYN="N">Particle Size</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013499" MajorTopicYN="N">Surface Properties</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">36 + GFP</Keyword>
        <Keyword MajorTopicYN="N">Cell-permeable peptides (CPPs)</Keyword>
        <Keyword MajorTopicYN="N">Dot1l</Keyword>
        <Keyword MajorTopicYN="N">plasmid DNA delivery</Keyword>
        <Keyword MajorTopicYN="N">supercharged protein</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare no competing financial interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>25</Day>
          <Hour>8</Hour>
          <Minute>46</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35075948</ArticleId>
        <ArticleId IdType="pmc">PMC8794074</ArticleId>
        <ArticleId IdType="doi">10.1080/10717544.2022.2030430</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Berry CC. (2008). Intracellular delivery of nanoparticles via the HIV-1 tat peptide. Nanomedicine
3:357–65.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18510430</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bono N, Ponti F, Mantovani D, Candiani G. (2020). Non-viral in vitro gene delivery: it is now time to set the bar!
Pharmaceutics
12:183.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7076396</ArticleId>
            <ArticleId IdType="pubmed">32098191</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen L, Guo X, Wang L, et al.  (2021). In silico identification and experimental validation of cellular uptake by a new cell penetrating peptide P1 derived from MARCKS. Drug Deliv
28:1637–48.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8330795</ArticleId>
            <ArticleId IdType="pubmed">34338123</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ding Y, Zhao X, Geng J, et al.  (2019). Intracellular delivery of nucleic acid by cell-permeable hPP10 peptide. J Cell Physiol
234:11670–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30515802</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Du X, Wang J, Zhou Q, et al.  (2018). Advanced physical techniques for gene delivery based on membrane perforation. Drug Deliv
25:1516–25.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6058615</ArticleId>
            <ArticleId IdType="pubmed">29968512</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Farshbaf M, Davaran S, Zarebkohan A, et al.  (2018). Significant role of cationic polymers in drug delivery systems. Artif Cells Nanomed Biotechnol
46:1872–91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29103306</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Geng J, Guo X, Wang L, et al.  (2020). Intracellular delivery of DNA and protein by a novel cell-permeable peptide derived from DOT1L. Biomolecules
10:217.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7072583</ArticleId>
            <ArticleId IdType="pubmed">32024261</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Geng J, Xia X, Teng L, et al.  (2022). Emerging landscape of cell-penetrating peptide-mediated nucleic acid delivery and their utility in imaging, gene-editing, and RNA-sequencing. J Control Release
341:166–83.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34822907</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo X, Chen L, Wang L, et al.  (2021). In silico identification and experimental validation of cellular uptake and intracellular labeling by a new cell penetrating peptide derived from CDN1. Drug Deliv
28:1722–36.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8409945</ArticleId>
            <ArticleId IdType="pubmed">34463179</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hou X, Zaks T, Langer R, Dong Y. (2022). Lipid nanoparticles for mRNA delivery. Nat Rev Mater
7:1–17.</Citation>
        </Reference>
        <Reference>
          <Citation>Ji Z, Xie Z, Zhang Z, et al.  (2017). Engineering intravaginal vaccines to overcome mucosal and epithelial barriers. Biomaterials
128:8–18.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28285195</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kardani K, Milani A, Shabani SH, Bolhassani A. (2019). Cell penetrating peptides: the potent multi-cargo intracellular carriers. Expert Opin Drug Deliv
16:1227–58.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31583914</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kato T, Yamashita H, Misawa T, et al.  (2016). Plasmid DNA delivery by arginine-rich cell-penetrating peptides containing unnatural amino acids. Bioorg Med Chem
24:2681–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27132868</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khan MM, Filipczak N, Torchilin VP. (2021). Cell penetrating peptides: a versatile vector for co-delivery of drug and genes in cancer. J Control Release
330:1220–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33248708</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim J, Eygeris Y, Gupta M, Sahay G. (2021). Self-assembled mRNA vaccines. Adv Drug Deliv Rev
170:83–112.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7837307</ArticleId>
            <ArticleId IdType="pubmed">33400957</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li M, Tao Y, Shu Y, et al.  (2015). Discovery and characterization of a peptide that enhances endosomal escape of delivered proteins in vitro and in vivo. J Am Chem Soc
137:14084–93.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26465072</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu H, Zeng F, Zhang M, et al.  (2016). Emerging landscape of cell penetrating peptide in reprogramming and gene editing. J Control Release
226:124–37.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26849918</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lu C, Li Z, Chang L, et al.  (2019). Efficient delivery of dsRNA and DNA in cultured silkworm cells for gene function analysis using PAMAM dendrimers system. Insects
11:12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7022533</ArticleId>
            <ArticleId IdType="pubmed">31877645</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lundstrom K. (2020). Application of viral vectors for vaccine development with a special emphasis on COVID-19. Viruses
12:1324.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7698750</ArticleId>
            <ArticleId IdType="pubmed">33218001</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma C, Malessa A, Boersma AJ, et al.  (2020). Supercharged proteins and polypeptides. Adv Mater
32:e1905309.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31943419</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma JL, Wang H, Wang YL, et al.  (2015). Enhanced peptide delivery into cells by using the synergistic effects of a cell-penetrating peptide and a chemical drug to alter cell permeability. Mol Pharm
12:2040–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25886885</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mangla B, Javed S, Kohli K, et al.  (2020). Reassessment of therapeutic applications of carbon nanotubes: a majestic and futuristic drug carrier. Crit Rev Ther Drug Carrier Syst
37:331–73.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32865929</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matta J, Maalouf R. (2019). Delivery of siRNA therapeutics: PLGA nanoparticles approach. Front Biosci (Schol Ed)
11:56–74.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30844736</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McNaughton BR, Cronican JJ, Thompson DB, Liu DR. (2009). Mammalian cell penetration, siRNA transfection, and DNA transfection by supercharged proteins. Proc Natl Acad Sci U S A
106:6111–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2659711</ArticleId>
            <ArticleId IdType="pubmed">19307578</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meacham JM, Durvasula K, Degertekin FL, Fedorov AG. (2014). Physical methods for intracellular delivery: practical aspects from laboratory use to industrial-scale processing. J Lab Autom
19:1–18.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4449156</ArticleId>
            <ArticleId IdType="pubmed">23813915</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Motevalli F, Bolhassani A, Hesami S, Shahbazi S. (2018). Supercharged green fluorescent protein delivers HPV16E7 DNA and protein into mammalian cells in vitro and in vivo. Immunol Lett
194:29–39.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29273425</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oliver SE, Gargano JW, Marin M, et al.  (2021). The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Moderna COVID-19 Vaccine – United States, December 2020. MMWR Morb Mortal Wkly Rep
69:1653–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33382675</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Prasse AA, Zauner T, Büttner K, et al.  (2014). Improvement of an antibody–enzyme coupling yield by enzyme surface supercharging. BMC Biotechnol
14:88.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4203919</ArticleId>
            <ArticleId IdType="pubmed">25326050</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pushparajah D, Jimenez S, Wong S, et al.  (2021). Advances in gene-based vaccine platforms to address the COVID-19 pandemic. Adv Drug Deliv Rev
170:113–41.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7789827</ArticleId>
            <ArticleId IdType="pubmed">33422546</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Regan MR, Huang YH, Kim YS, et al.  (2007). Variations in promoter activity reveal a differential expression and physiology of glutamate transporters by glia in the developing and mature CNS. J Neurosci
27:6607–19.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6672708</ArticleId>
            <ArticleId IdType="pubmed">17581948</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ruwizhi N, Aderibigbe BA. (2020). The efficacy of cholesterol-based carriers in drug delivery. Molecules
25:4330.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7570546</ArticleId>
            <ArticleId IdType="pubmed">32971733</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schutze-Redelmeier MP, Kong S, Bally MB, Dutz JP. (2004). Antennapedia transduction sequence promotes anti tumour immunity to epicutaneously administered CTL epitopes. Vaccine
22:1985–91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15121311</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shukla RS, Qin B, Cheng K. (2014). Peptides used in the delivery of small noncoding RNA. Mol Pharm
11:3395–408.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4186677</ArticleId>
            <ArticleId IdType="pubmed">25157701</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sidorova NY, Hung S, Rau DC. (2010). Stabilizing labile DNA–protein complexes in polyacrylamide gels. Electrophoresis
31:648–53.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3125985</ArticleId>
            <ArticleId IdType="pubmed">20108261</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Skwarczynski M, Toth I. (2019). Cell-penetrating peptides in vaccine delivery: facts, challenges and perspectives. Ther Deliv
10:465–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31462173</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Suresh B, Ramakrishna S, Kim H. (2017). Cell-penetrating peptide-mediated delivery of Cas9 protein and guide RNA for genome editing. Methods Mol Biol
1507:81–94.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27832534</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thompson DB, Cronican JJ, Liu DR. (2012). Engineering and identifying supercharged proteins for macromolecule delivery into mammalian cells. Methods Enzymol
503:293–319.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3505079</ArticleId>
            <ArticleId IdType="pubmed">22230574</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thompson DB, Villaseñor R, Dorr BM, et al.  (2012). Cellular uptake mechanisms and endosomal trafficking of supercharged proteins. Chem Biol
19:831–43.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3408882</ArticleId>
            <ArticleId IdType="pubmed">22840771</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Uhl P, Grundmann C, Sauter M, et al.  (2020). Coating of PLA-nanoparticles with cyclic, arginine-rich cell penetrating peptides enables oral delivery of liraglutide. Nanomedicine
24:102132.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31783138</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang H, Ma J, Yang Y, et al.  (2016a). Highly efficient delivery of functional cargoes by a novel cell-penetrating peptide derived from SP140-like protein. Bioconjug Chem
27:1373–81.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27070736</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang H, Ma JL, Yang YG, et al.  (2016b). Efficient therapeutic delivery by a novel cell-permeant peptide derived from KDM4A protein for antitumor and antifibrosis. Oncotarget
7:49075–90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5226491</ArticleId>
            <ArticleId IdType="pubmed">27081693</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang H, Zhang M, Zeng F, Liu C. (2016c). Hyperosmotic treatment synergistically boost efficiency of cell-permeable peptides. Oncotarget
7:74648–57.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5342692</ArticleId>
            <ArticleId IdType="pubmed">27213591</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang H, Zhong CY, Wu JF, et al.  (2010). Enhancement of TAT cell membrane penetration efficiency by dimethyl sulphoxide. J Control Release
143:64–70.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20025914</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu J, Li J, Wang H, Liu CB. (2018). Mitochondrial-targeted penetrating peptide delivery for cancer therapy. Expert Opin Drug Deliv
15:951–64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30173542</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu Q, Cheng Q, Yuan S, et al.  (2015). A cell-penetrating protein designed for bimodal fluorescence and magnetic resonance imaging. Chem Sci
6:6607–13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5506616</ArticleId>
            <ArticleId IdType="pubmed">28757964</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang J, Luo Y, Shibu MA, et al.  (2019). Cell-penetrating peptides: efficient vectors for vaccine delivery. Curr Drug Deliv
16:430–43.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6637094</ArticleId>
            <ArticleId IdType="pubmed">30760185</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang K, Cheng X, Zhao L, et al.  (2020). Direct functional protein delivery with a peptide into neonatal and adult mammalian inner ear in vivo. Mol Ther Methods Clin Dev
18:511–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7477795</ArticleId>
            <ArticleId IdType="pubmed">32953927</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang M, Zhao X, Geng J, et al.  (2019). Efficient penetration of Scp01-b and its DNA transfer abilities into cells. J Cell Physiol
234:6539–47.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30230543</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Y, Røise JJ, Lee K, et al.  (2018). Recent developments in intracellular protein delivery. Curr Opin Biotechnol
52:25–31.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6082692</ArticleId>
            <ArticleId IdType="pubmed">29486392</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou N, Wu J, Qin YY, et al.  (2017). Novel peptide MT23 for potent penetrating and selective targeting in mouse melanoma cancer cells. Eur J Pharm Biopharm
120:80–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28860066</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
